



GEDEON RICHTER

Extraordinary announcement

New tax on the Hungarian pharmaceutical industry

Budapest, Hungary – 27 December 2022 – Gedeon Richter Plc. (hereinafter the “Company”) announces that under Government Decree 582/2022 (XII.23.) on the extra profit taxes the expected magnitude of supplementary pharmaceutical tax payable by the Company for the year 2022 is expected to be approximately HUF 28 billion. On 4 June 2022 the Government of Hungary issued a decree (Government Decree of 197/2022. (VI.4.)) imposing new taxes on a number of industries, which has been extended on 23 December 2022 to the pharmaceutical industry (Government Decree of 582/2022 (XII.23.)). The extraordinary pharmaceutical tax is levied on the actual business year’s annual net sales of pharmaceutical products and active pharmaceutical ingredients as defined by the Local Tax Act and is payable for the years 2022 and 2023. Under the terms of the decree the expected magnitude of supplementary tax payable by the Company for the year 2022 is approximately HUF 28 billion. The tax is expected to be accounted under Other expenses thus will proportionally lower the Company’s operating profit and free cash-flow for 2022. Other elements of financial targets set for 2022 and released in the public domain are kept unchanged.

Gedeon Richter Plc.

[Chemical Works of Gedeon Richter Plc.](#)

Headquarters: H-1103 Budapest, Gyömrői út 19-21., Hungary • Postal address: H-1475 Budapest 10., Pf. 27., Hungary
Phone: +36 1 431 4000 • Fax: +36 1 260 6650, +36 1 260 4891 • Company Court of Budapest-Capital Tribunal Reg. No. Cg. 01-10-040944
EU Community VAT Identification No: HU 10484878 • Internet: www.richter.hu